NeuroVive Pharmaceutical
Cyclosporine-based mitochondrial-protecting pharmaceuticals for the treatment.
Launch date
Employees
Market cap
AUD55.7m
Enterprise valuation
AUD51m (Public information from Sep 2024)
Share price
SEK0.251 0QDU.L
Company register number 556595-6538
Lund Municipality Skane County (HQ)
Financials
Estimates*
| SEK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.0m | <1m | <1m | - | - | - | - |
| % growth | 1438 % | (93 %) | (79 %) | - | - | - | - |
| EBITDA | (58.0m) | (121m) | (82.6m) | (108m) | (116m) | (138m) | (157m) |
| % EBITDA margin | (2900 %) | (80667 %) | (266452 %) | - | - | - | - |
| Profit | (60.0m) | (123m) | (85.0m) | (95.5m) | (119m) | (141m) | (161m) |
| % profit margin | (3000 %) | (82000 %) | (274194 %) | - | - | - | - |
| EV / revenue | 113.3x | 1456.7x | 6100.0x | - | - | - | - |
| EV / EBITDA | -3.9x | -1.8x | -2.3x | -2.4x | -2.4x | -1.9x | -1.7x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $3.3m | Post IPO Equity | |
| N/A | $7.5m | Post IPO Equity | |
* | SEK2.5m | Grant | |
$4.1m | Grant | ||
| Total Funding | AUD6.8m | ||
Related Content
Recent News about NeuroVive Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
